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Introduction. Neovascularisation of atherosclerotic plaques correlates with increased plaque instability and subsequent
risk of vascular complications. Diabetics have widespread atherosclerotic involvement of the arterial tree and a more
aggressive form of the disease culminating in increased plaque instability. This results in a greater incidence of ischaemic
sequelae than in non-diabetics. Previous studies have examined neovascularisation as a marker of plaque instability in both
the carotid and coronary territories and revealed a greater degree in both symptomatic and diabetic patients. This is the first
study to examine intimal neovascularisation in lower limb peripheral arterial disease.
Methods. Arterial specimens were taken from 20 patients, ten of whom were type 2 diabetics, undergoing major lower limb
amputation for unreconstructable critical ischaemia. Sections were stained with H&E for morphological assessment and
inflammatory cell characterisation. Additional sections underwent immunohistochemical staining for CD31 and von-
Willebrand Factor (vWF) and the number of intimal vessels per four 40x magnification fields assessed.
Results. There was a more prominent inflammatory infiltrate in diabetic subjects compared to non-diabetic controls.
Diabetic patients had a greater degree of intimal neovascularisation compared to controls with a median of 11.5 and 2.0
vessels per field respectively (P< 0.05). Sub-group analysis revealed that diabetic patients medicating with HMG-CoA
Reductase inhibitors (Statins) had a greater degree of neovascularisation compared to those not taking this class of
medication.
Conclusion. Diabetic patients with critical limb ischaemia requiring amputation demonstrate a greater degree of plaque
intimal neovascularisation and inflammatory infiltrate compared to their non-diabetic counterparts. This may explain the
greater plaque instability and subsequent cardiovascular complications seen in these patients.
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Atherosclerosis is the dominant cause of morbidity
and mortality in patients with diabetes, being respon-
sible for 80% of deaths and nearly three quarters of
hospitalisations.1 The angiopathy seen in diabetes
has distinct features separate from the more common
atherosclerosis and has been extensively studied, es-
pecially in relation to coronary,2 carotid3 and retinal4
arterial disease. In particular, comparisons of coro-
nary and carotid intimal neovascularisation between
diabetics and non-diabetics demonstrate increased
numbers of intimal new vessels in the former.2,3
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is a marker of the advanced plaque and is associated
with extensive chronic inflammatory cell infiltrate and
elevated levels of the pro-angiogenic cytokines such as
basic FibroblastGrowthFactor (bFGF)5 andVascularEn-
dothelial Growth Factor (VEGF).4 Atherosclerosis is
characterised by a chronic fibro-proliferative inflamma-
tory infiltrate with a significant angiogenic component,
most noticeable in advanced disease.6,7 In diabetic pa-
tients, the atherosclerotic process is more widespread,
involving a greater portion of the arterial tree, with par-
ticular propensity for the smaller diameter vessels. In-
flammation and plaque neovascularisation have both
been identified as major characteristics of plaques at
risk of rupture and are associated with increased poten-
tial to becomesymptomatic.8 Indeed, higher intimal ves-
sel counts are seen in those with symptomatic carotid
and coronary disease compared to patients who were
symptom free.3,9,10 However, there remains a paucity
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arteries.
The aetiology and origin of these intimally located
new blood vessels is less clear. Increased depth of the
atherosclerotic plaque results in the core cellular compo-
nents being unable to survive solely on diffusion for
their metabolic needs and so neovascularisation is re-
quired to meet demands for nutrients and oxygen.11
These new vessels are thought to develop from capillar-
ies originating from the adventitial vasculature and vasa
vasora penetrating the media to reach the intima12e18
and, to a lesser degree, from the lumen itself.15
Although it was previously held that arterial events
such as thrombosis, embolism or plaque haemorrhage
were a consequence of luminal narrowing alone, it is
nowbroadly accepted that both the activity and themor-
phology of individual plaques, precipitates infarction
and worsening ischaemia following either atheroma
rupture or endothelial erosion.19 The importance of inti-
mal neovascularisation in acute disease of peripheral
vascular beds is unknown. Intimal capillaries are more
prevalent in the fibrous cap and shoulder.Here the accu-
mulation of inflammatory cells contributes to plaque
instabilityby cytokineactivationanddestructionbypro-
teolytic enzymes causing the plaque to rupture where
the fibrous cap is thinnest.11,12,16 Atheromatous rupture
and haemorrhage arises in regions of fragile newly
formed microvessels within advanced plaques, which
is significant in the pathogenesis of acute coronary syn-
dromes12 and carotid embolisation.10
It was our hypothesis that atheroma in diabetic pa-
tients with critical lower limb ischaemia demonstrates
a higher level of intimal angiogenesis. Given that inti-
mal neovascularisation is associated with increased
plaque fragility and risk of complications, this could
explain the greater risk of arterial events seen in the
diabetic population. This study aims to investigate in-
timal neovascularisation and the degree of inflamma-
tion of non diabetic and diabetic patients with
advanced lower limb atherosclerosis.
Methods
Ethical approval was obtained from the local research
ethics committee for Central Manchester Healthcare
trust.
Patients undergoing major amputation for unrec-
onstructable, chronic lower limb arterial disease
were recruited to the study. Samples were obtained
from ten patients with type 2 diabetes mellitus and
ten non-diabetics for comparison. Patient data was
collected for demographics, concurrent medications,
serum lipid profile and level of disease on colourEur J Vasc Endovasc Surg Vol 33, March 2007duplex scanning. Following completion of the ampu-
tation, arterial samples were harvested from the distal
superficial femoral artery or distal popliteal vessels
for above and below knee amputations respectively.
Samples were fixed in formaldehyde, paraffin wax
embedded and cut into 5 mm sections. Sections were
stained with haematoxylin and eosin (H&E) for mor-
phological analysis and assessment of inflammatory
infiltrate. Additional sections underwent staining
with immunohistochemistry for CD31 and von Wille-
brand Factor (vWF) to clearly visualise the endothe-
lium and hence delineate microvessel density within
the intima. Slides were counterstained with elastica-
van Gieson to more clearly define the internal elastic
lamina, facilitating visualisation of the intima.
Sections were graded according to American Heart
Association (AHA) guidelines6,7 and then viewed at
40x magnification for assessment of the number of in-
timal vessels per field. The number of inflammatory
cells within the intima and media were also assessed.
Analysis of each slide was carried out separately by
four independent investigators who were blinded to
the patient’s diabetic status. In each slide, evaluation
of the number of intimal vessels was carried out in
four different quadrants of the arterial wall.
Counts were correlated with patient demographics
and concurrent medications to determine any further
association.
Of the 20 samples obtained for the study, 18 were
suitable for analysis. Twelve specimens were from
the distal superficial femoral artery (SFA) while in
six patients, samples were taken from the below
knee popliteal artery. Six of the samples in each group
were from the distal SFA.
The two patient groups were well matched for age,
co-morbidity and anti-platelet use as shown in Table 1.
Non-diabetic patients had a lower prevalence of statin
use (50% versus 75%). Diabetic subjects had a greater
incidence of anticoagulant usage; this was primarily
due to warfarin prescriptions for atrial fibrillation.
The diabetic cohort also had higher serum cholesterol,
HDL and triglyceride concentrations.
Data was evaluated using the Mann-Whitney
U-test using StatsDirect statistical software version
2.4.1 (StatsDirect ltd, Cheshire, UK). Significance was
taken at a P value of 0.05 or less. Inter-observer
variability was evaluated using the Fleiss-Nee-Landis
test.
Results
Two of the samples from diabetic subjects were
AHA class VI plaques and had delaminated after
321Plaque Neovascularisation in Lower Limb Atheromaprocessing and therefore were unsuitable for analysis.
All remaining intimal plaques were classified AHA
grade IV or V and so were relatively homogenous in
terms of severity of plaque morphology. Inter-
observer variability was evaluated using the Fleiss-
Nee-Landis test (where k¼ 0.03).
In both groups, an infiltrate consisting of predomi-
nantly chronic inflammatory cells was found with the
diabetic subjects having a median of 40.0 cells (range
12e82) per four 40x objectives compared to 28.5 cells
(range 15e67) in the controls although this difference
was not significant (P¼ 0.26).
CD31 staining revealed a median of 9.5 and 2.0 ves-
sels in diabetics and controls respectively (P< 0.05).
vWF staining identified a greater number of vessels
within the arterial intima, with a median of 11.5 ves-
sels per four 40x objectives in diabetic patients, com-
pared to the control specimens which had a median
of 2.0 vessels (P< 0.05) (Fig. 1). Representative images
of non-diabetic sections with sparse intimal new ves-
sel formation are shown in Fig. 2(a,b). Typical appear-
ances of sections of the arterial wall of diabetic
patients demonstrating more prominent intimal neo-
vascularisation are shown in Fig. 3(a,b).
Although there was a difference in the overall
counts between the two staining methods (see Fig. 1),
a similar degree of difference in median counts
between the diabetic and the non-diabetic controls
was found, regardless of the staining method used.
While the numbers in this analysis are small none-
theless, sub group analysis with regard to diabetic
Table 1. Patient demographics
Diabetics* Controls (non-diabetic)
Number 8 10
M:F 5:3 3:7
Mean age 70.4 (56e89) 69.7 (53e86)
Anti-platelet agent (%) 6/8 (75) 10/10 (100)
Anticoagulants (%) 4/8 (50) 0/10 (0)
Statin use (%) 6/8 (75) 5/10 (50)
Insulin Use (%) 2 (25%) 0
Mean serum
Cholesterol mmol/L
4.4 4.0
(3.1e5.7) (2.8e5.6)
Mean HDL mmol/L 0.98 (0.7e1.4) 1.20 (0.9e2.1)
Mean Triglycerides
mmol/L (range)
2.1 1.5
(1.3e3.7) (1.2e1.9)
Level of disease:
- aorto-iliac 2 5
- femoral 7 8
- distal 7 9
Sample location:
- SFA 6 6
- Distal popliteal 2 4
* All diabetic subjects were either medicating with oral hypogly-
caemic agents (87.5%) or insulin. One patient was taking both
insulin and an oral hypoglycaemic agent.status and statin therapy showed that, in the diabetic
group, a trend towards a greater degree of neovascu-
larisation was present if they were medicating with
a statin although this failed to reach statistical signif-
icance. A median of 16.5 vessels were seen in the sta-
tin users compared to 5.5 in those diabetics who were
not taking a statin (P¼ 0.07). In the non-diabetic
group, no such difference was seen with a median
of 2.0 vessels per field in both patients both taking
and not taking a statin (P¼ 0.34).
Discussion
It has been over a century since the role of intra-
plaque neovascularisation in atherosclerotic plaque
progression and in the development of complications
was first postulated.13 The normal human intima is
devoid of blood vessels, the cells within it obtaining
oxygen and nutrients via diffusion from the arterial
lumen.5,18 Angiogenesis only becomes a feature
when the intima has proliferated beyond a critical
thickness with these new vessels originating from
capillaries within the vasa vasorum and, to a lesser
degree, from the lumen itself.12e18
The mechanism by which this occurs is poorly
understood but may represent a response by plaque
tissue to hypoxia and inflammation with the produc-
tion of angiogenic factors such as bFGF, VEGF and
platelet derived growth factor.4,5,18,20,21 The original
concept that neovascularisation is a late feature in
plaque progression has recently been challenged as
intimal neovascularisation has been demonstrated
within plaques of atheroma even in less advanced
stages of the disease with new vessels present in
lesions as early as AHA class II plaques.3 Diabetes is
known to promote the advancement of atherosclerosis
Fig. 1. Box and Whisker plot for median number of intimal
vessels per four 40x objectives.Eur J Vasc Endovasc Surg Vol 33, March 2007
322 A. Carter et al.Fig. 2. Control specimens with immunohistochemical staining for CD31 (a) and vWF (b) at 40x magnification. The black
arrows indicate areas of neovascularisation.in coronary arteries.22 This is thought to be the result of
several mechanisms such as apoprotein and lipopro-
tein distribution abnormalities, a procoagulant state,
insulin resistance and hyperinsulinaemia. Addition-
ally, glycation of proteins within the plasma and arte-
rial wall, glycation and oxidation abnormalities and
also hormone, growth factor and cytokine enhanced
smooth muscle proliferation and foam cell formation
also play a role.22
Macrophages are the most abundant inflammatory
cell present in atherosclerotic lesions and are responsi-
ble for the production of themultitude of cytokines cen-
tral to atherogenesis. Endothelial cell activation results
in leukocyte adhesion and migration into the athero-
sclerotic lesion resulting in destabilisation of the plaque
through the release of proteases such as those of the
matrix metalloproteinase family produced by plaqueEur J Vasc Endovasc Surg Vol 33, March 2007macrophages.10,21 Macrophages adherent to the en-
dothelial lining of intra-plaque blood vessels have
also been demonstrated and are more prevalent in
advanced plaques.10 The proximity of these vessels
to inflammatory infiltrates and the expression of adhe-
sion molecules on the endothelium of vessels within
the plaque both suggest that this microvasculature
may aid recruitment of inflammatory cells into lesions
thereby starting a positive feedback mechanism.11 It is
not surprising therefore that an increase in macro-
phage infiltration was found in the diabetic subjects.
The diabetic patients who were on statin therapy
had a greater degree of neovascularisation when com-
pared to those not.
Statins are thought to work in two ways. First by
a lipid lowering effect which has been shown to sup-
press proteolytic activity, decrease endothelial cellFig. 3. Diabetic patient specimen stained for both CD31 (a) and vWF (b) at 40x magnification. The black arrows indicate
areas of neovascularisation.
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their direct anti-inflammatory properties on plaque
macrophages with resultant plaque stabilisation.24,25
However, recent studies have questioned their role
in plaque angiogenesis. Statins have been proposed
to have an anti-apoptotic effect on endothelial progen-
itor cells thereby enhancing the pro-angiogenic effects
of these drugs.26 Further work however has demon-
strated a biphasic, dose dependant effect on angiogen-
esis. At low dose, 10 nM serum concentration, statins
were shown to be pro-angiogenic due to decreased
expression of plasminogen activator inhibitor-1 and
thrombospondin-1.27 At higher doses, 1e10 mM, the
statins proved to be anti-angiogenic, possibly by di-
minished production of interleukin (IL)-8 and by inhi-
bition of urokinase plasminogen activator synthesis.27
This may imply that although the statins could stabi-
lise the plaque at higher concentrations by their direct
anti-inflammatory effect and anti-angiogenic effects,
at low concentrations they may actually increase pla-
que fragility by encouraging neovascularisation.
The two most commonly used markers for neovas-
cularisation are the endothelial markers CD31 and
vWF. Interestingly, the vWF stain was found to be
more sensitive when visualising the neovascularisa-
tion, but gave a higher level of background staining,
hence the discrepancy in the number of vessels seen
with the CD31 and vWF stains.
In this patient sample, we have demonstrated that
diabetic patients with critical lower limb ischaemia
have a greater degree of intimal neovascularisation
when compared to non-diabetic controls highlighting
the importance of inflammation in later stages of
atherosclerosis. Inflammation is known to be an
important factor in the development of the unstable
atherosclerotic plaque.4e10 This may explain the in-
crease in complications related to atherosclerosis
seen in the diabetic population with diabetes itself act-
ing as a pro-inflammatory condition. Further work
into the subject is underway, with particular focus
on the role of statins in plaque angiogenesis.
The numbers in this study were small, causing dif-
ficulties in making concrete conclusions. This is espe-
cially so with regard to statin usage and the degree of
neovascularisation in the diabetic population. Only
two out of the eight diabetics were not taking this
class of medication. Accordingly, we cannot state
with confidence the significance of these results. Fur-
ther experiments are required to investigate this
hypothesis further. This is surprising as statins have
been shown to stabilise atherosclerotic plaques and
therefore it would be expected that those subjects
treated with these medications would show a lesser
degree of intimal neovascularisation.23Acknowledgements
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